Kyntra Bio, Inc.
KYNB
$6.82
-$0.19-2.71%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.28M | 1.08M | 1.35M | 2.74M | 3.14M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.28M | 1.08M | 1.35M | 2.74M | 3.14M |
| Cost of Revenue | 7.55M | 1.15M | 5.95M | 9.43M | 22.12M |
| Gross Profit | -6.27M | -75.00K | -4.60M | -6.69M | -18.99M |
| SG&A Expenses | 7.25M | 5.30M | 7.06M | 8.11M | 8.35M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.80M | 6.45M | 13.01M | 17.53M | 30.47M |
| Operating Income | -13.52M | -5.37M | -11.66M | -14.79M | -27.33M |
| Income Before Tax | -14.61M | -13.15M | -13.78M | -16.76M | -8.66M |
| Income Tax Expenses | 0.00 | -- | -92.00K | 2.00K | 2.00K |
| Earnings from Continuing Operations | -14.61M | -13.15M | -13.68M | -16.77M | -8.67M |
| Earnings from Discontinued Operations | 390.00K | 213.78M | 6.08M | 21.41M | 26.65M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.22M | 200.64M | -7.60M | 4.64M | 17.98M |
| EBIT | -13.52M | -5.37M | -11.66M | -14.79M | -27.33M |
| EBITDA | -13.51M | -5.18M | -11.44M | -14.47M | -26.98M |
| EPS Basic | -3.51 | 49.61 | -1.88 | 1.15 | 4.46 |
| Normalized Basic EPS | -2.26 | -1.01 | -2.07 | -2.58 | -4.47 |
| EPS Diluted | -3.51 | 49.61 | -1.88 | 1.15 | 4.46 |
| Normalized Diluted EPS | -2.26 | -1.01 | -2.07 | -2.58 | -4.47 |
| Average Basic Shares Outstanding | 4.05M | 4.04M | 4.04M | 4.04M | 4.03M |
| Average Diluted Shares Outstanding | 4.05M | 4.04M | 4.04M | 4.04M | 4.03M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |